Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Q1 Revenues Rise 3 Percent

Premium

Thermo Fisher Scientific this week reported first-quarter revenue growth of three percent year-over-year, with revenues for its Analytical Technologies segment, which includes the company's life sciences mass spectrometry business, climbing 9 percent to $1.18 billion from $1.08 billion a year ago.

During a conference call after the release of the company's results, President and CEO Marc Casper said Thermo's clinical diagnostics business posted double-digit growth in the quarter and highlighted the company's Brahms sepsis biomarker assay as particularly "strongly performing."

He also touched on the company's acquisition of chromatography firm Dionex (PM 12/17/2010), noting that the European Commission is reviewing the deal and it is expected to close in mid-May.

For the first quarter, Thermo Fisher posted net income of $252.2 million, or $.64 per share, up 9 percent from $232.3 million, or $.56 per share, a year ago. On an adjusted basis, EPS was $.92, compared to $.82 a year ago, beating Wall Street estimates of $.88.

The company increased its R&D spending to $74.8 million, up 13 percent from $66.1 million a year ago. Its SG&A costs increased 4 percent to $606.7 million from $584 million a year ago.

As of April 2, Thermo Fisher had $2.79 billion in cash and cash equivalents.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.